Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Morishita Jintan Co., Ltd. (4524:JPX), powered by AI.
Morishita Jintan Co., Ltd. is currently trading at ¥2,153. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Morishita Jintan Co., Ltd. on Alpha Lenz.
Morishita Jintan Co., Ltd.'s P/E ratio is 16.1.
“Morishita Jintan Co., Ltd. trades at a P/E of 16.1 (fair value) with modest ROE of 4.5%. 3Y revenue CAGR of 10.1% highlights clear growth momentum.”
Ask for details →Morishita Jintan Co., Ltd. is a renowned Japanese company primarily involved in the production and distribution of pharmaceuticals and health-related products. Established in 1893, it carved a niche with its innovative herbal medicine and encapsulated products. Over the years, Morishita Jintan has expanded its offerings to include dietary supplements, oral hygiene products, and environmental materials. The company is particularly noted for its encapsulation technology, which enhances the delivery and absorption of active ingredients. This technology has significant implications not only in pharmaceuticals but also across food and cosmetics industries. Morishita Jintan Co., Ltd. plays a crucial role in the health and wellness sector, catering to a diverse consumer base both domestically in Japan and internationally. Its long-standing reputation and focus on quality make it a key player in the market, constantly striving to contribute to healthy lifestyles through its innovative solutions.
“Morishita Jintan Co., Ltd. trades at a P/E of 16.1 (fair value) with modest ROE of 4.5%. 3Y revenue CAGR of 10.1% highlights clear growth momentum.”
Ask for details →Morishita Jintan Co., Ltd. (ticker: 4524) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 356 employees. Market cap is $8.8B.
The current price is 2,153 with a P/E ratio of 16.09x and P/B of 0.72x.
ROE is 4.50% and operating margin is 6.34%. Annual revenue is $12.8B.